Abstract:Background: As a Class A bioterrorism agent, botulinum neurotoxin serotype A (BoNT/A) carries the risk of being used by terrorists to cause mass poisoning. The microneedle (MN) patch has a great potential for application as a novel vaccine delivery method. The aim of this study is to develop a thermally stable, dissolving microneedle patch for the delivery of a recombinant protein vaccine using a recombinant C-terminal heavy chain of BoNT/A (Hc of BoNT/A, AHc) to prevent botulism. Methods: Fish gelatin, a natural non-toxic and bacteriostatic material, was selected as the microneedle matrix for the preparation of the dissolving microneedle vaccine. Subsequently, the mechanical performance, bacteriostatic properties, vaccination effect, and stability of the microneedle patches were evaluated using instruments such as the displacement-force test station and optical coherence tomography (OCT) scanner. Results: Fish gelatin matrix at high concentrations has good bacteriostatic properties, and excellent mechanical performance and vaccination effect, meeting the necessities of a vaccine. In both in vivo and in vitro neutralization experiments, MN vaccines containing different antigen doses achieved the same protective efficacy as subcutaneous vaccinations, protecting mice against 106 LD50 of BoNT/A injected intraperitoneally. Thermal stability analysis of the MN vaccines revealed that the fish gelatin matrix protected the AHc vaccine from protein denaturation even after 7 days of storage at 37 °C and enabled the vaccine patches to maintain good immunogenicity and protective efficacy even after 6 months of storage at room temperature. Conclusion: In this study, we successfully prepared a bacteriostatic MN patch using a fish gelatin matrix that not only has a good vaccination effect, but also obviates the need for a cold chain for the AHc vaccine, providing the possibility of rapid, painless, and large-scale vaccination.

The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate

Protection with a Recombinant Hc Ofclostridium Botulinumneurotoxin Serotype A Fromescherichia Colias an Effective Subunit Vaccine

Evaluation of a Recombinant Hc of Clostridium botulinum Neurotoxin Serotype F as an Effective Subunit Vaccine

Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system

Binding Activity and Immunogenic Characterization of Recombinant C-terminal Quarter and Half of the Heavy Chain of Botulinum Neurotoxin Serotype A

Production and Evaluation of a Recombinant Subunit Vaccine Against Botulinum Neurotoxin Serotype B Using a 293E Expression System.

Expression, purification and characterization of the receptor-binding domain of botulinum neurotoxin serotype B as a vaccine candidate

The Receptor Binding Domain of Botulinum Neurotoxin Serotype A (BoNT/A) Inhibits BoNT/A and BoNT/E Intoxications In Vivo

Development and Evaluation of Candidate Vaccine and Antitoxin Against Botulinum Neurotoxin Serotype F

Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E

Enhanced Immune Responses Using Plasmid DNA Replicon Vaccine Encoding the Hc Domain of Clostridium Botulinum Neurotoxin Serotype A

Recombinant L-HN Fusion Antigen Derived from the L and HN Domains of Botulinum Neurotoxin B Stimulates a Protective Antibody Response Against Active Neurotoxin

Functional EL-HN Fragment as a Potent Candidate Vaccine for the Prevention of Botulinum Neurotoxin Serotype E

Cloning, high level expression and immunogenicity of 1163-1256 residues of C-terminal heavy chain of C. botulinum neurotoxin type E

Novel platform for engineering stable and effective vaccines against botulinum neurotoxins A, B and E

Improved Immunogenicity and Protective Efficacy of A Replicon Dna Vaccine Encoding the Hc Domain of Botulinum Neurotoxin Serotype A by Electric Pulses and Protein Boosting

Co-expression of Tetanus Toxin Fragment C in Escherichia Coli with Thioredoxin and Its Evaluation As an Effective Subunit Vaccine Candidate

A Recombinant Chimeric Protein Containing B Chains of Ricin and Abrin is an Effective Vaccine Candidate.

High-Level and Soluble Expressions of Botulinum Neurotoxin Serotype B Protective Antigen Hc Domain in Escherichia coli

A Thermostable Dissolving Microneedle Vaccine with Recombinant Protein of Botulinum Neurotoxin Serotype A

Development and Preclinical Evaluation of a New F(ab')₂ Antitoxin Against Botulinum Neurotoxin Serotype A.